Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy

Dear Colleagues,

The Special Issue “Tumor Immune Microenvironment and Novel Strategies for Cancer Immunotherapy” encompasses a multidisciplinary field at the intersection of oncology, immunology, and therapeutics. It involves the study of complex interactions between cancer cells and the immune system within the microenvironment of tumors, as well as the development and implementation of innovative approaches to harness the immune system for treating cancer. The scope of this Special Issue includes investigating the cellular and molecular components of the tumor microenvironment, including tumor-infiltrating immune cells (such as T cells, B cells, natural killer cells, and myeloid cells), stromal cells, cytokines, chemokines, and extracellular matrix components; identifying biomarkers and predictive signatures associated with the tumor immune microenvironment; novel strategies for cancer immunotherapy aiming to manipulate the tumor immune microenvironment to enhance anti-tumor immune responses and overcoming immune evasion mechanisms employed by cancer cells; recognizing the complexity of the tumor immune microenvironment; combinatorial approaches that integrate immunotherapy with conventional treatments (such as chemotherapy, radiation therapy, and targeted therapy) or other immunomodulatory agents; combination therapies which have the potential to synergistically enhance therapeutic efficacy and overcome resistance mechanisms; translating preclinical findings and novel immunotherapeutic strategies into clinical practice, which requires rigorous clinical trials, biomarker validation studies, and collaborative efforts between researchers, clinicians, regulatory agencies, and industry partners.

In summary, this Special Issue encompasses a broad spectrum of research aimed at elucidating the complex interplay between tumors and the immune system, as well as the development of innovative immunotherapeutic approaches to combat cancer.

Dr. Sidra Islam
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• tumor microenvironment cancer immunotherapy
• immune markers
• tumor infilterating immune cells
• tumors